Description: Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Home Page: www.roche.com
Konzern Hauptsitz
Basel,
4070
Switzerland
Phone:
41 61 688 11 11
Officers
| Name | Title |
|---|---|
| Dr. Severin Schwan Ph.D. | CEO & Exec. Director |
| Dr. Alan Hippe | Chief Financial & Information Officer |
| Ms. Cristina A. Wilbur | Chief People Officer |
| Dr. Johannes Carolus Clevers M.D., Ph.D. | Head of Roche Pharma Research & Early Devel. |
| Dr. Thomas Schinecker | Chief Exec. Officer of Roche Diagnostics |
| Mr. William N. Anderson | Chief Exec. Officer of Roche Pharmaceuticals |
| Dr. Bruno Eschli | Head of Investor Relations |
| Ms. Claudia Bockstiegel | Gen. Counsel |
| Ms. Pascale Schmidt | Chief Compliance Officer |
| Ms. Barbara Schadler | Head of Group Communications |
Exchange: OTCQX
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 14.4718 |
|---|---|
| Trailing PE: | 16.374 |
| Price-to-Book MRQ: | 9.8089 |
| Price-to-Sales TTM: | 3.9935 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 100920 |